echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > China's first storage-resistant mRNA vaccine will start production next month

    China's first storage-resistant mRNA vaccine will start production next month

    • Last Update: 2021-09-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    China's first novel coronavirus mRNA vaccine will be put into production next month


    The new crown mRNA pneumonia vaccine by the Academy of Military Medicine Chinese Academy of Military Sciences, love Bo Biological Technology Co.


    Recently, China's first new coronavirus mRNA vaccine production workshop was completed and put into production in Yuxi, Yunnan


     

     

    The total investment in the new base is expected to be 520 million yuan


     

     

    mRNA is a natural molecule that provides instructions to human cells, stimulates the body's immunity to produce antigens, and fights corresponding diseases


    The mRNA gene encoding the S protein is directly injected into the human body, and the human cell is used to synthesize the S protein in the human body to stimulate the body to produce antibodies


    In layman's terms, this is equivalent to handing over a detailed virus file to the body's immune system


     

     

    The mRNA vaccine is currently the vaccine with the highest protection rate (95%) among the results of phase III clinical trials announced globally


    At the same time, its R&D technology threshold is relatively high


    There are several reasons for China's comprehensive promotion of mRNA vaccines:

    1.


    The selection of vaccine antigen targets used in China is more precise, and the induced neutralizing antibodies have higher specificity


    2.


    China's mRNA vaccine core raw materials and equipment have been produced locally, which means that once production approval is obtained, production capacity will be able to achieve rapid expansion to meet supply


    3.


    The mRNA produced in China uses a single pre-filled injection format that can be stored at room temperature for a week or at 4°C for a long time


     

    At present, in addition to the smooth progress in the research and development of mRNA vaccines, China's recombinant vaccines based on traditional technologies are already at the forefront of the world


    According to statistics, up to now, 5 vaccine projects in China have entered phase III clinical trials, and vaccination has been initiated in more than 10 countries, and no serious adverse reactions have been reported
    .

     

    (Source: Internet, for reference only)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.